News | November 20, 2021
U.S. FDA allows Pfizer and Moderna booster doses for all
This is a shot in the arm for the vaccine manufacturers
This is a shot in the arm for the vaccine manufacturers
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
The aim is to support Pharmacovigilance programme across the countries in the region
The interim data combines three mRNAs into one therapy injected directly into the tumour
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
It plans to double its network to 50 centres across India in the next three years
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
Subscribe To Our Newsletter & Stay Updated
